Efficacy, toxicity, and pattern of response and progression in patients with high-grade gliomas treated with bevacizumab and irinotecan: Experience in one center.

e12553 Background: The prognosis for patients with recurrent glioblastoma multiforme is poor, with a median survival of 12 to 24 weeks. The combination of irinotecan and bevacizumab was showed as a...